I agree in that Covid was an unexpected bonus to t
Post# of 72444
(Total Views: 748)
Posted On: 11/14/2021 4:50:47 PM
I agree in that Covid was an unexpected bonus to the Brilacidin platform and has cost the company a lot of time and money, two items of which we have little left and which could really hurt the company in the future.
But Covid opened up so many more avenues for B, mainly in the study by govt RBLs as to over 20 other viruses currently ongoing.
Right now if we get good secondary results or even if we just get some positive indications and the Compassionate Use data really highlights that B at higher dosages and longer dosings can really kick some Covid butt, then my belief is that Leo should immediately make a deal for B-Covid even if the terms are much less than he desired, though far more than the AS deal which I thought was near crap. Let B-Covid deal provide the money to advance B in both OM and IBD without massive dilution and let the associated BP pick up the tab for the nasal and inhaler delivery systems and push B thru the FDA (which I do not think is our friend in any form but a direct hindrance) at a far greater speed than IPIX could do alone.
I also thought the PR of 11/10 could have included further information to make the results look as utterly devastating to the company as it did. Really a ***tty PR in my opinion.
I now have lost some faith in Leo's ability to realize we need things done now and quit haggling for the best deal possible on Covid - let's concentrate on not letting IPIX slip into a state where it's ability to stay solvent without massive dilution is the main focus. Stockholders have backed this play long enough and its about time we see some concern returned in our favor.
I still wonder if we did not get the dosage we wanted for the trial why we didn't lower our primary objective goals? Why put the fate of the company so much on the line - IMO this was done also in the Prurisol trial where our primary objective was sky high.
But Covid opened up so many more avenues for B, mainly in the study by govt RBLs as to over 20 other viruses currently ongoing.
Right now if we get good secondary results or even if we just get some positive indications and the Compassionate Use data really highlights that B at higher dosages and longer dosings can really kick some Covid butt, then my belief is that Leo should immediately make a deal for B-Covid even if the terms are much less than he desired, though far more than the AS deal which I thought was near crap. Let B-Covid deal provide the money to advance B in both OM and IBD without massive dilution and let the associated BP pick up the tab for the nasal and inhaler delivery systems and push B thru the FDA (which I do not think is our friend in any form but a direct hindrance) at a far greater speed than IPIX could do alone.
I also thought the PR of 11/10 could have included further information to make the results look as utterly devastating to the company as it did. Really a ***tty PR in my opinion.
I now have lost some faith in Leo's ability to realize we need things done now and quit haggling for the best deal possible on Covid - let's concentrate on not letting IPIX slip into a state where it's ability to stay solvent without massive dilution is the main focus. Stockholders have backed this play long enough and its about time we see some concern returned in our favor.
I still wonder if we did not get the dosage we wanted for the trial why we didn't lower our primary objective goals? Why put the fate of the company so much on the line - IMO this was done also in the Prurisol trial where our primary objective was sky high.
(7)
(0)